Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Rescue of rhesus macaques from the lethality of aerosolized ricin toxin.

Roy CJ, Ehrbar DJ, Bohorova N, Bohorov O, Kim D, Pauly M, Whaley K, Rong Y, Torres-Velez FJ, Vitetta ES, Didier PJ, Doyle-Meyers L, Zeitlin L, Mantis NJ.

JCI Insight. 2019 Jan 10;4(1). pii: 124771. doi: 10.1172/jci.insight.124771. [Epub ahead of print]

2.

The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.

BitMansour A, Pop LM, Vitetta ES.

PLoS One. 2016 Dec 13;11(12):e0167618. doi: 10.1371/journal.pone.0167618. eCollection 2016.

3.

Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Pincus SH, Song K, Maresh GA, Hamer DH, Dimitrov DS, Chen W, Zhang MY, Ghetie VF, Chan-Hui PY, Robinson JE, Vitetta ES.

J Virol. 2017 Jan 18;91(3). pii: e01955-16. doi: 10.1128/JVI.01955-16. Print 2017 Feb 1.

4.

Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, Robinson JE, Hu SL.

J Virol. 2017 Jan 18;91(3). pii: e01360-16. doi: 10.1128/JVI.01360-16. Print 2017 Feb 1.

5.

Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF.

Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11300-11305. Epub 2016 Sep 20.

6.

The Immunogenicity of Peptoid-Protein Conjugates.

Case A, Desmond A, Lopes D, Dye K, Mapes K, Ruback S, Pop I, Kim JK, Chakravarty P, Smallshaw JE, Pop LM, Vitetta ES.

J Vaccines Vaccin. 2016 Aug;7(4). pii: 329. Epub 2016 Jul 11.

7.

Recent advances in the development of vaccines against ricin.

Brey RN 3rd, Mantis NJ, Pincus SH, Vitetta ES, Smith LA, Roy CJ.

Hum Vaccin Immunother. 2016 May 3;12(5):1196-201. doi: 10.1080/21645515.2015.1124202. Epub 2016 Jan 25.

8.

Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.

Roy CJ, Brey RN, Mantis NJ, Mapes K, Pop IV, Pop LM, Ruback S, Killeen SZ, Doyle-Meyers L, Vinet-Oliphant HS, Didier PJ, Vitetta ES.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3782-7. doi: 10.1073/pnas.1502585112. Epub 2015 Mar 9.

9.

A reevaluation of CD22 expression in human lung cancer.

Pop LM, Barman S, Shao C, Poe JC, Venturi GM, Shelton JM, Pop IV, Gerber DE, Girard L, Liu XY, Behrens C, Rodriguez-Canales J, Liu H, Wistuba II, Richardson JA, Minna JD, Tedder TF, Vitetta ES.

Cancer Res. 2014 Jan 1;74(1):263-71. doi: 10.1158/0008-5472.CAN-13-1436.

10.

TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens.

Sturge CR, Benson A, Raetz M, Wilhelm CL, Mirpuri J, Vitetta ES, Yarovinsky F.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10711-6. doi: 10.1073/pnas.1307868110. Epub 2013 Jun 10.

11.

Partial depletion of regulatory T cells does not influence the inflammation caused by high dose hemi-body irradiation.

Ma S, Richardson JA, Bitmansour A, Solberg TD, Pidikiti R, Song K, Stojadinovic S, Vitetta ES, Meyer JJ.

PLoS One. 2013;8(2):e56607. doi: 10.1371/journal.pone.0056607. Epub 2013 Feb 11.

12.

Pillars article: T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J. Exp. Med. 1982. 155: 734-748.

Isakson PC, Puré E, Vitetta ES, Krammer PH.

J Immunol. 2013 Feb 1;190(3):849-63. No abstract available.

13.

Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Vitetta ES, Smallshaw JE, Schindler J.

Clin Vaccine Immunol. 2012 Oct;19(10):1697-9. Epub 2012 Aug 22.

14.

Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Wachsmann MB, Pop LM, Vitetta ES.

J Investig Med. 2012 Apr;60(4):643-63. doi: 10.2310/JIM.0b013e31824a4d79. Review.

15.

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

Liu XY, Pop LM, Schindler J, Vitetta ES.

MAbs. 2012 Jan-Feb;4(1):57-68. doi: 10.4161/mabs.4.1.18348.

16.

Passive and active vaccination strategies to prevent ricin poisoning.

Pincus SH, Smallshaw JE, Song K, Berry J, Vitetta ES.

Toxins (Basel). 2011 Sep;3(9):1163-84. doi: 10.3390/toxins3091163. Epub 2011 Sep 15. Review.

17.

A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.

Tsai LK, Pop LM, Liu X, Vitetta ES.

Toxins (Basel). 2011 Apr;3(4):409-19. doi: 10.3390/toxins3040409. Epub 2011 Apr 6.

18.

Structure of RiVax: a recombinant ricin vaccine.

Legler PM, Brey RN, Smallshaw JE, Vitetta ES, Millard CB.

Acta Crystallogr D Biol Crystallogr. 2011 Sep;67(Pt 9):826-30. doi: 10.1107/S0907444911026771. Epub 2011 Aug 9.

19.

Ricin vaccine development.

Smallshaw JE, Vitetta ES.

Curr Top Microbiol Immunol. 2012;357:259-72. doi: 10.1007/82_2011_156. Review.

PMID:
21805396
20.

The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells.

Marches R, Mikoryak C, Wang RH, Pantano P, Draper RK, Vitetta ES.

Nanotechnology. 2011 Mar 4;22(9):095101. doi: 10.1088/0957-4484/22/9/095101. Epub 2011 Jan 24.

PMID:
21258147
21.
22.

Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication.

Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES.

Vaccine. 2010 Jul 19;28(32):5315-22. doi: 10.1016/j.vaccine.2010.05.045. Epub 2010 Jun 1.

23.

A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.

Smallshaw JE, Vitetta ES.

Vaccine. 2010 Mar 11;28(12):2428-35. doi: 10.1016/j.vaccine.2009.12.081. Epub 2010 Jan 12.

24.

A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.

Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES, Schindler J.

J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41. doi: 10.1097/MPH.0b013e3181bdf211.

PMID:
19875969
25.

Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines.

Pop IV, Pop LM, Ghetie MA, Vitetta ES.

Leuk Lymphoma. 2009 Jul;50(7):1155-62. doi: 10.1080/10428190903046722.

PMID:
19557637
26.

Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies.

Marches R, Chakravarty P, Musselman IH, Bajaj P, Azad RN, Pantano P, Draper RK, Vitetta ES.

Int J Cancer. 2009 Dec 15;125(12):2970-7. doi: 10.1002/ijc.24659.

27.
28.

Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes.

Chakravarty P, Marches R, Zimmerman NS, Swafford AD, Bajaj P, Musselman IH, Pantano P, Draper RK, Vitetta ES.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8697-702. doi: 10.1073/pnas.0803557105. Epub 2008 Jun 16.

29.

Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.

Powell DJ Jr, Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA.

J Immunother. 2008 Feb-Mar;31(2):189-98. doi: 10.1097/CJI.0b013e31815dc0e8.

30.

Engineering therapeutic monoclonal antibodies.

Liu XY, Pop LM, Vitetta ES.

Immunol Rev. 2008 Apr;222:9-27. doi: 10.1111/j.1600-065X.2008.00601.x. Review.

PMID:
18363992
31.

Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.

Pop I, Pop L, Vitetta ES, Ghetie MA.

Oncol Rep. 2008 Apr;19(4):889-95.

PMID:
18357372
32.

RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.

Smallshaw JE, Richardson JA, Vitetta ES.

Vaccine. 2007 Oct 16;25(42):7459-69. Epub 2007 Aug 30.

33.

Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ.

Blood. 2007 Sep 1;110(5):1689-97. Epub 2007 May 3.

34.

Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.

Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E.

Adv Cancer Res. 2007;97:189-202. Review.

PMID:
17419946
35.

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.

Herrera L, Stanciu-Herrera C, Morgan C, Ghetie V, Vitetta ES.

Leuk Lymphoma. 2006 Nov;47(11):2380-7.

PMID:
17107913
36.
37.

Immunology. Considering therapeutic antibodies.

Vitetta ES, Ghetie VF.

Science. 2006 Jul 21;313(5785):308-9. No abstract available.

PMID:
16857927
38.

Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics.

Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE.

Int Immunopharmacol. 2006 May;6(5):791-9. Epub 2005 Dec 22.

PMID:
16546710
39.

A pilot clinical trial of a recombinant ricin vaccine in normal humans.

Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R, Schindler J.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2268-73. Epub 2006 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4328.

40.

A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro.

Vaclavkova P, Cao Y, Wu LK, Michalek J, Vitetta ES.

Bone Marrow Transplant. 2006 Mar;37(6):559-67.

PMID:
16444279
41.

Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.

Vallera DA, Brechbiel MW, Burns LJ, Panoskaltsis-Mortari A, Dusenbery KE, Clohisy DR, Vitetta ES.

Clin Cancer Res. 2005 Nov 1;11(21):7920-8.

42.
43.
44.

Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.

Amrolia PJ, Mucioli-Casadei G, Huls H, Heslop HE, Schindler J, Veys P, Vitetta ES, Brenner MK.

Cytotherapy. 2005;7(2):116-25. Review.

PMID:
16047416
45.

Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Savelyeva N, King CA, Vitetta ES, Stevenson FK.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10987-92. Epub 2005 Jul 21.

46.

Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.

Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD.

Cancer Res. 2005 Jul 15;65(14):6371-9.

47.

Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.

Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES.

Vaccine. 2005 Sep 15;23(39):4775-84.

PMID:
15961194
48.

The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.

Pop LM, Liu X, Ghetie V, Vitetta ES.

Int Immunopharmacol. 2005 Jul;5(7-8):1279-90. Epub 2005 Apr 26.

PMID:
15914332
49.

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ.

Blood. 2005 Aug 1;106(3):1123-9. Epub 2005 Apr 7.

50.

The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3.

Smallshaw JE, Coleman E, Spiridon C, Vitetta ES.

J Immunother. 2004 Nov-Dec;27(6):419-24.

PMID:
15534485

Supplemental Content

Loading ...
Support Center